Abbott stock skidded early Wednesday after the health giant reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales.

The fate of hundreds of pending cases against Abbott and Mead Johnson hang in the balance with the latest dismissal.

Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults ...

Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.30 per share, up from $1.21 per ...

The win is Abbott’s third in a row in federal court in Chicago where hundreds of cases over specialized formulas for preterm ...

Abbott Laboratories (NYSE:ABT) ranks among the best medical device stocks to invest in. Benchmark began coverage of Abbott ...

A federal judge has thrown out a second case against Abbott Laboratories over the safety of its formula for babies born prematurely — a decision with potential implications for hundreds of other ...

Compared to the aggregate P/E ratio of the 48.51 in the Health Care Equipment & Supplies industry, Abbott Laboratories Inc. has a lower P/E ratio of 16.02. Shareholders might be inclined to think that ...

That being said, even among dividend stocks, many aren't worth sticking with for the long term. Let's consider one dividend payer that is: Abbott Laboratories ( ABT +0.40%). This healthcare leader has ...

WASHINGTON AP - State officials say drugmaker Abbott Laboratories will pay $22.5 million to settle allegations that it tried to block generic competition to a popular cholesterol medication.The ...

The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based ...